|
Company:
|
ATYR PHARMA INC (LIFE)
|
|
Form Type:
|
4
|
|
Filing Date:
|
5/8/2020
|
|
CIK:
|
0001339970
|
|
Address:
|
3545 JOHN HOPKINS COURT, STE #250
|
|
City, State, Zip:
|
SAN DIEGO, California 92121
|
|
Telephone:
|
858-731-8389
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$3.60
|
Change:
-0.34 (-8.63%)
|
Trade Time:
Jan 27
|
Market Cap:
$36.67M
|
|
|
|
|
|
|
Description of Business
|
|
We are a biotherapeutics company engaged in the discovery and development of
innovative medicines based on novel immunological pathways. We have concentrated
our research and development efforts on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA synthetases. Built on
more than a decade of foundational science on extracellular tRNA synthetase
biology and its effect on immune responses, we have built a global intellectual
property estate directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets, such as
neuropilin-2 (NRP2).
Our primary focus is on ATYR1923, a clinical stage product candidate which binds
to the NRP2 receptor and is designed to down regulate immune engagement in
interstitial lung diseases (ILDs).
|
|
|
|